These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Phenytoin disposition in obesity. Determination of loading dose. Abernethy DR; Greenblatt DJ Arch Neurol; 1985 May; 42(5):468-71. PubMed ID: 3994563 [TBL] [Abstract][Full Text] [Related]
7. Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Lind MJ; Margison JM; Cerny T; Thatcher N; Wilkinson PM Cancer Chemother Pharmacol; 1989; 25(2):139-42. PubMed ID: 2557169 [TBL] [Abstract][Full Text] [Related]
8. Carbamazepine pharmacokinetics in obese and lean subjects. Caraco Y; Zylber-Katz E; Berry EM; Levy M Ann Pharmacother; 1995 Sep; 29(9):843-7. PubMed ID: 8547729 [TBL] [Abstract][Full Text] [Related]
9. Lidocaine disposition in obesity. Abernethy DR; Greenblatt DJ Am J Cardiol; 1984 Apr; 53(8):1183-6. PubMed ID: 6702701 [TBL] [Abstract][Full Text] [Related]
10. The effect of obesity on apparent volume of distribution of theophylline. Rohrbaugh TM; Danish M; Ragni MC; Yaffe SJ Pediatr Pharmacol (New York); 1982; 2(1):75-83. PubMed ID: 7110759 [TBL] [Abstract][Full Text] [Related]
11. Dose-independent pharmacokinetics of digoxin in humans. Ochs HR; Greenblatt DJ; Bodem G; Harmatz JS Am Heart J; 1978 Oct; 96(4):507-11. PubMed ID: 358815 [TBL] [Abstract][Full Text] [Related]
12. Obesity, sex, and acetaminophen disposition. Abernethy DR; Divoll M; Greenblatt DJ; Ameer B Clin Pharmacol Ther; 1982 Jun; 31(6):783-90. PubMed ID: 7075126 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of digoxin in low-birth-weight infants. Collins-Nakai RL; Schiff D; Ng PK Dev Pharmacol Ther; 1982; 5(1-2):86-97. PubMed ID: 7151640 [TBL] [Abstract][Full Text] [Related]
14. Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). Abernethy DR; Greenblatt DJ; Divoll M; Shader RI J Pharm Sci; 1982 Aug; 71(8):942-4. PubMed ID: 6811726 [TBL] [Abstract][Full Text] [Related]
16. Digoxin-quinidine interaction Pharmacokinetic evaluation. Hager WD; Fenster P; Mayersohn M; Perrier D; Graves P; Marcus FI; Goldman S N Engl J Med; 1979 May; 300(22):1238-41. PubMed ID: 431681 [TBL] [Abstract][Full Text] [Related]
17. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. Abernethy DR; Greenblatt DJ; Divoll M; Shader RI J Lab Clin Med; 1983 Jun; 101(6):873-80. PubMed ID: 6133901 [TBL] [Abstract][Full Text] [Related]
18. Doxorubicin clearance in the obese. Rodvold KA; Rushing DA; Tewksbury DA J Clin Oncol; 1988 Aug; 6(8):1321-7. PubMed ID: 3411343 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of digoxin in sheep: limitations of the use of biological half-life for interspecies extrapolation. Dix LP; Bai SA; Rogers RA; Anderson DL; Riviere JE Am J Vet Res; 1985 Feb; 46(2):470-2. PubMed ID: 3994115 [TBL] [Abstract][Full Text] [Related]
20. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay. Cheng JW; Charland SL; Shaw LM; Kobrin S; Goldfarb S; Stanek EJ; Spinler SA Pharmacotherapy; 1997; 17(3):584-90. PubMed ID: 9165563 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]